We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teleflex (TFX) Completes Buyout of Hemostatic Goods Producer
Read MoreHide Full Article
Teleflex Incorporated (TFX - Free Report) recently completed its previously announced acquisition of Z-Medica, LLC, a renowned manufacturer of hemostatic products. Financial terms (as stated during the time of initiation of the definitive acquisition deal toward the end of October), included making an upfront cash payment of $500 million along with other agreement-related terms.
For investors’ note, the buyout is not expected to significantly impact Teleflex’s balance sheet for 2020. However, benefits are expected to be accrued from 2021.
With the recent buyout, Teleflex aims to strengthen its Vascular Access business across the globe.
Rationale Behind the Acquisition
Z-Medica’s hemostatic technologies include products which contribute to hemorrhage control with cost-effective and efficient bleeding-control solutions. Z-Medica’s portfolio includes three main brands — QuikClot, Combat Gauze and QuikClot Control+, which utilize a proprietary technology consisting of gauze infused with kaolin. Notably, QuikClot Control+ is the first hemostatic dressing indicated for temporary control of Class III or Class IV bleeding in the internal organ space. With the buyout, these technologies will be integrated into Teleflex’s portfolio, thus enabling it to leverage strength in the hospital, Emergency Medical Services and military call points. These differentiated products are expected to complement the EZ-IO and EZPLAZ product portfolio of Teleflex.
Industry Prospects
Per a report by Verified Market Research, the global hemostatic agents’ market was valued at $3.78 billion in 2019 and is anticipated to reach $6.22 billion by 2027 at a CAGR of 6.4%. Factors like growing incidents of patients suffering from bleeding disorders, rising number of trauma and surgical cases, and technological advancements are expected to drive the market.
Given the market potential, the buyout is expected to significantly boost Teleflex’s business.
Notable Developments
Teleflex has witnessed a few developments across its businesses over the past few months.
The company, during its third-quarter earnings call in October, confirmed that its Vascular Access segment witnessed modestly higher-than-expected demand due to the pandemic. This demand surge contributed to the growth of the segment’s revenues from the Americas during the quarter.
The same month, Teleflex announced the expansion of its UroLift System portfolio with the introduction of the UroLift Advanced Tissue Control System. Further, the company released the Arrow ErgoPack Complete CVC System in the same month.
Teleflex received the FDA’s 510(k) clearance to expand the Indications for Use of its Arrow EZ-IO Intraosseous Vascular Access System in October. With the expanded indication, the device can be used for up to 48 hours when alternate intravenous access is not available or reliably established in patients aged 12 years and above.
Price Performance
Shares of the company have gained 7.9% in the past year compared with the industry and S&P 500’s 23.9% and 18% growth, respectively.
Zacks Rank & Key Picks
Currently, Teleflex carries a Zacks Rank #3 (Hold).
Some other better-ranked stocks from the broader medical space are Hologic, Inc. (HOLX - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Laboratory Corporation of America Holdings (LH - Free Report) or LabCorp.
IDEXX’s long-term earnings growth rate is estimated at 15.8%. It currently carries a Zacks Rank #2 (Buy).
LabCorp’s long-term earnings growth rate is estimated at 10.1%. The company presently carries a Zacks Rank #2.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Teleflex (TFX) Completes Buyout of Hemostatic Goods Producer
Teleflex Incorporated (TFX - Free Report) recently completed its previously announced acquisition of Z-Medica, LLC, a renowned manufacturer of hemostatic products. Financial terms (as stated during the time of initiation of the definitive acquisition deal toward the end of October), included making an upfront cash payment of $500 million along with other agreement-related terms.
For investors’ note, the buyout is not expected to significantly impact Teleflex’s balance sheet for 2020. However, benefits are expected to be accrued from 2021.
With the recent buyout, Teleflex aims to strengthen its Vascular Access business across the globe.
Rationale Behind the Acquisition
Z-Medica’s hemostatic technologies include products which contribute to hemorrhage control with cost-effective and efficient bleeding-control solutions. Z-Medica’s portfolio includes three main brands — QuikClot, Combat Gauze and QuikClot Control+, which utilize a proprietary technology consisting of gauze infused with kaolin. Notably, QuikClot Control+ is the first hemostatic dressing indicated for temporary control of Class III or Class IV bleeding in the internal organ space. With the buyout, these technologies will be integrated into Teleflex’s portfolio, thus enabling it to leverage strength in the hospital, Emergency Medical Services and military call points. These differentiated products are expected to complement the EZ-IO and EZPLAZ product portfolio of Teleflex.
Industry Prospects
Per a report by Verified Market Research, the global hemostatic agents’ market was valued at $3.78 billion in 2019 and is anticipated to reach $6.22 billion by 2027 at a CAGR of 6.4%. Factors like growing incidents of patients suffering from bleeding disorders, rising number of trauma and surgical cases, and technological advancements are expected to drive the market.
Given the market potential, the buyout is expected to significantly boost Teleflex’s business.
Notable Developments
Teleflex has witnessed a few developments across its businesses over the past few months.
The company, during its third-quarter earnings call in October, confirmed that its Vascular Access segment witnessed modestly higher-than-expected demand due to the pandemic. This demand surge contributed to the growth of the segment’s revenues from the Americas during the quarter.
The same month, Teleflex announced the expansion of its UroLift System portfolio with the introduction of the UroLift Advanced Tissue Control System. Further, the company released the Arrow ErgoPack Complete CVC System in the same month.
Teleflex received the FDA’s 510(k) clearance to expand the Indications for Use of its Arrow EZ-IO Intraosseous Vascular Access System in October. With the expanded indication, the device can be used for up to 48 hours when alternate intravenous access is not available or reliably established in patients aged 12 years and above.
Price Performance
Shares of the company have gained 7.9% in the past year compared with the industry and S&P 500’s 23.9% and 18% growth, respectively.
Zacks Rank & Key Picks
Currently, Teleflex carries a Zacks Rank #3 (Hold).
Some other better-ranked stocks from the broader medical space are Hologic, Inc. (HOLX - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Laboratory Corporation of America Holdings (LH - Free Report) or LabCorp.
Hologic’s long-term earnings growth rate is estimated at 17.4%. The company presently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
IDEXX’s long-term earnings growth rate is estimated at 15.8%. It currently carries a Zacks Rank #2 (Buy).
LabCorp’s long-term earnings growth rate is estimated at 10.1%. The company presently carries a Zacks Rank #2.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>